Outcome

This study involved collaboration between MS patients clinicians and scientists to design lab experiments reflecting real-world use of hyperbaric oxygen therapy by MS patients. The findings showed that exposing human brain endothelial cells to oxygen levels typical for MS treatments resulted in reduced ICAM-1 a molecule important in inflammatory cell migration across the blood-brain barrier.

Introduction

This study explores the potential benefits of hyperbaric oxygen therapy (HBOT) for people living with multiple sclerosis (MS). Collaborating with MS patients researchers designed laboratory experiments to replicate the oxygen therapy conditions commonly used by these patients: 100% oxygen at 1.5 atmospheres absolute (ATA) for 60 minutes. The study focused on the effects of HBOT on human brain endothelial cells which form part of the blood-brain barrier. Results showed a significant reduction in ICAM-1 a molecule associated with inflammatory cell migration in the brain under these treatment conditions. This finding suggests that HBOT might help reduce neuroinflammation in MS by influencing endothelial cell behavior.

Results

The study explored the physiological effects of hyperbaric oxygen therapy (HBOT) on multiple sclerosis (MS) by closely simulating treatment conditions used by MS patients. MS patients commonly use HBOT at 1.5 atmospheres absolute (ATA) for 60 minutes which includes exposure to 100% oxygen. To replicate these conditions human brain endothelial cells were subjected to 152 mmHg O2 for 60 minutes in laboratory settings both with and without pressure. This oxygen level corresponds to the 20% O2 achievable via hyperbarics. The experiments revealed a significant reduction in ICAM-1 (CD54) levels a molecule associated with inflammatory cell migration across the blood-brain barrier under these oxygen conditions.

Additionally the research integrated feedback from people living with MS to design more accurate lab protocols. These patient-informed methods aimed to reflect real-life HBOT usage providing insights into its role in reducing neuroinflammation. The study highlighted how collaborative research with MS patients can enhance the understanding of HBOT’s potential benefits particularly its anti-inflammatory effects on brain cells.

Conclusion

The study on the physiological effects of hyperbaric oxygen therapy (HBOT) for Multiple Sclerosis (MS) offers significant insights into how HBOT might potentially benefit MS patients by reducing neuroinflammation. By engaging MS patients in the research design the scientists accurately replicated the common treatment conditions used by MS patients in real-life settings specifically exposing human brain endothelial cells to 100% oxygen at 1.5 ATA for 60 minutes. The laboratory results showed a noteworthy reduction in ICAM-1 a molecule implicated in the migration of inflammatory cells across the blood-brain barrier. This suggests that HBOT may have an anti-inflammatory effect on the brain which could be beneficial for managing MS. Importantly this research highlights the importance of patient involvement in designing studies that closely mirror actual therapeutic practices thus enhancing the relevance and applicability of the findings. While no conflicts of interest were declared the study was supported by the Royal Devon and Exeter Foundation Trust underscoring the collaborative effort to understand and potentially optimize HBOT for MS.